Skip to main content

Acufree

The company Tinnitech is born

The Tinnitech company was founded by a group of technologists and doctors dedicated to creating an innovative solution to the unresolved problem of tinnitus in Italy and in the world. The founders were joined by Professor Bruno Brandimarte, a historical student of Fermi’s “Panisperna boys”, a former professor of physics and anatomy, a serial patent holder and above all an expert in “coordination between medical devices and pharmacology”. Brandimarte becomes head of research and main inventor of the project in November 2016, when our first patent is filed.


 

First prototypes

Between 2017 and 2018, the complex functioning of “physio-chemical” technology designed for the treatment of tinnitus was further developed.
The first prototypes were developed under the name of “Silencer”.


 

First trials

The first trials are started using ENT doctors with a different setting and operation from today: technology on a “smart control unit” with medical devices which were activated but not autonomous.


 

The Technology evolves

European rules on medical devices change radically: all pre-2021 clinical trials are no longer considered, so they must be repeated according to the new criteria of the MDR-745 directive. The promising preliminary 2020 clinical results are set aside; everything is started again from scratch. Tinnitech initiates Phase Two. The Technology evolves: the control panel disappears, the devices become intelligent, operating with autonomous units; a 3rd active element is integrated, more applications and healing functions are integrated. The 2nd Patent is filed in March 2021. The foundations are laid for the “synchronous multimodal therapy” : 3 elements acting simultaneously, in anti-tinnitus function.

Acufree is born

Collaboration begins with the Tor Vergata University General Hospital for clinical trials and diagnostic plus therapeutic development. Protocol T0001/22 is agreed and approved and clinical experiments on 55 subjects begin.
The device changes its name: from Silencer to Acufree.


 

Distribution of the device in Italy

The release of the clinical results and benefits for patients in Italy begins. The dream of the founders of Tinnitech to treat the many Italians suffering from tinnitus with this innovative and particularly promising therapy comes true.


Clinical and Technological results

The Technology is consolidated with additional IT capabilities, multi-frequency, basic tinnitus, advanced mobility and telemedicine.

The two patents are granted on an international scale and for all three parameters of intellectual property and industrial invention.

In June, the Tor Vergata Hospital protocol T0001/22 is completed. The results are very promising and are disseminated to the SIO (national ENT congress) and in the Press.

From September 2023, work has been carried out on the transformation of the “Acufree prototype” into the first anti-tinnitus serial production with “synchronized multimodal
methodology”.

In October 2023 well-known Prof. Burioni published a famous book on multiple therapies for incurable diseases, as happy coincidence with the dissemination in the national media of our success with our own, unique tinnitus “multimodal therapy” (i.e. simultaneous aggression of the diseases).

In November, the positive results of Tor Vergata protocol T0001/22 are made official after 12 months,, that is: tinnitus relief that lasts! The 1-year improvements are presented at the SIAF – national congress of audiology, speaker Prof. Di Girolamo, ENT Director of Tor Vergata and scientific director of the clinical study.